Journal
JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 135, Issue 1, Pages 13-15Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/jid.2014.362
Keywords
-
Categories
Funding
- National Institute for Health Research [ACF-2013-01-001] Funding Source: researchfish
- Wellcome Trust Funding Source: Medline
Ask authors/readers for more resources
Omalizumab, an anti-IgE mAb, has recently been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of chronic idiopathic urticaria. Saini et al (2014) (this issue) report on ASTERIA I, a 40-week randomized, double-blinded, placebo-controlled phase III trial evaluating omalizumab for the treatment of this disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available